# CJC-1295 Ipamorelin as a Growth Hormone Secretagogue > CJC-1295 Ipamorelin as a growth hormone secretagogue: how a GHRH analogue and a ghrelin-receptor secretagogue combine to raise GH supra-additively. Cited. A secretagogue makes the body release its own GH rather than supplying GH directly. Here the GHRH arm and the ghrelin arm combine — and why that adds up. ## The gist A **growth hormone secretagogue** is anything that makes your pituitary release its own growth hormone (GH), instead of injecting GH from outside. CJC-1295 Ipamorelin is a two-part secretagogue: CJC-1295 mimics the body's natural "release GH" signal (GHRH), and ipamorelin hits a second, separate switch — the ghrelin receptor — that also triggers GH. Two switches, pressed together, get a bigger GH pulse than either alone. Why use a secretagogue instead of GH itself? Because it works with the body's own controls: the GH still comes out in natural bursts, and the normal feedback brakes stay in place. The trade-off is that you depend on a working pituitary, and — for this specific pair — that the combination has never been formally trialed. The class as a whole looks well tolerated short-term, with raised blood sugar as the main flag. ## What "secretagogue" means, and the two families Secretagogue simply means a substance that triggers secretion — here, GH secretion. Two distinct families do this. The first is GHRH analogues: copies of growth-hormone-releasing hormone that bind the GHRH receptor on pituitary somatotrophs and drive GH through the cAMP pathway. CJC-1295 (and its short-acting form, Mod GRF 1-29) belongs here, as do sermorelin and tesamorelin. The second family is the GH-releasing peptides (GHRPs) or ghrelin-receptor agonists, which bind GHS-R1a and drive GH through a calcium pathway. Ipamorelin belongs here, and it is the first one selective enough to release GH without also raising cortisol or ACTH, even at doses 200-fold above its half-maximal GH dose [2]. ## Why combining the two arms beats either alone Because the two families signal through independent pathways, pressing both switches releases more GH than the sum of each — supra-additivity. In 18 normal men, submaximal GHRP doses combined with GHRH stimulated GH synergistically, the two acting through independent mechanisms [3]. At the receptor level, co-activating the GHS and GHRH receptors in transfected cells produced about twice the cAMP signal of GHRH alone [4]. That is the entire mechanistic case for pairing a GHRH analogue (CJC-1295) with a ghrelin-receptor secretagogue (ipamorelin): each does a real job, and together they do more than apart. The ghrelin arm also eases off somatostatin, the brake on GH, adding to the effect. ## The duration trick, and the caveat The CJC-1295 arm adds a duration trick the older secretagogues lack. Its Drug Affinity Complex covalently binds albumin, extending the GH signal to days rather than minutes [5][1], so the secretagogue effect becomes a sustained background on which the ipamorelin pulse layers. A single dose raised GH for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and pulsatility was preserved rather than abolished [8]. The caveat that belongs on every page about this stack: the synergy data used related peptides, not the exact CJC-1295 + ipamorelin pair, and there is no peer-reviewed human pharmacology study of the pre-mixed combination. The secretagogue principle is well established; the specific fixed blend is uncharacterized, unapproved, and prohibited at all times in sport under WADA Section S2. ## How a secretagogue differs from giving growth hormone directly It helps to contrast a growth hormone secretagogue with the alternative it is often compared to: injecting GH itself. Exogenous GH delivers a fixed amount on a flat curve and overrides the body's own release rhythm. A secretagogue instead leans on the pituitary, so the GH that appears still comes out in natural bursts under the body's feedback control — during sustained CJC-1295 stimulation, basal GH rose about 7.5-fold yet pulse frequency and amplitude were unchanged [8]. The downstream IGF-1 negative feedback that normally restrains the axis stays in the loop, which is the mechanistic argument for a gentler ceiling on the response. The price of that approach is dependence on a functioning pituitary and, for this specific pair, the absence of any trial confirming the secretagogue effect for the fixed blend. ## Where this secretagogue sits among the others Among growth hormone secretagogues, the CJC-1295 + ipamorelin pairing is distinctive for combining a long-acting GHRH analogue with a clean, selective ghrelin-receptor agent. Other secretagogues illustrate the range: sermorelin is a short-acting GHRH analogue; tesamorelin is a GHRH analogue with the strongest human body-composition data, including visceral- and hepatic-fat reductions in a 2026 meta-analysis [7]; and the orally active MK-677 raised mean 24-hour GH about 97% and IGF-1 in healthy elderly subjects over 28 days [10]. What sets ipamorelin apart within the secretagogue class is that it releases GH as effectively as older GH-releasing peptides without dragging cortisol or ACTH along [2] — the selectivity that makes it the preferred ghrelin-arm partner for a GHRH analogue. The practical upshot is that this combination tries to capture the best of both secretagogue families at once: the multi-day, pulsatility-preserving GHRH drive of CJC-1295 and the sharp, side-effect-light GH pulse of a selective ghrelin-receptor agent. No single-molecule secretagogue does both, which is the entire reason the two are paired rather than used alone — and the reason the untested-blend caveat matters, since that combined profile has never been measured directly in a person. --- A graphene-lab readout of the CJC-1295 and ipamorelin literature — the GH and IGF-1 numbers, the DAC-versus-Mod-GRF half-life split, and the selectivity data logged to source, with the empty space where the fixed-blend trial should be left lit on the panel; no clinic behind the console and nothing here dosed, dispensed, or sold.